High-priority targets include established therapeutic genes such as IGF1, for which mecasermin represents an existing FDA-approved treatment, and GRIA1/GRIN2A, which are targeted by memantine and other glutamate receptor modulators currently used in Alzheimer’s disease management. This evidence concerns the gene GRIN2A and early-onset autosomal dominant Alzheimer disease.